



Human adipose tissue-derived stromal cells act as functional pericytes in mice and suppress high-glucose-induced proinflammatory activation of bovine retinal endothelial cells

Ghazaleh Hajmoussa¹ · Ewa Przybył¹ · Frederick Pfister² · Genaro A. Paredes-Juarez¹ · Kondaiah Moganti³ · Stephanie Busch² · Jeroen Kuipers⁴ · Ingeborg Klaassen⁵ · Marja J. A. van Luyn¹ · Guido Krenning¹ · Hans-Peter Hammes² · Martin C. Harmsen¹

Received: 3 May 2018 / Accepted: 5 July 2018 / Published online: 27 August 2018
© The Author(s) 2018

Abstract

Aims/hypothesis The immunomodulatory capacity of adipose tissue-derived stromal cells (ASCs) is relevant for next-generation cell therapies that aim to reverse tissue dysfunction such as that caused by diabetes. Pericyte dropout from retinal capillaries underlies diabetic retinopathy and the subsequent aberrant angiogenesis.

Methods We investigated the pericytic function of ASCs after intravitreal injection of ASCs in mice with retinopathy of prematurity as a model for clinical diabetic retinopathy. In addition, ASCs influence their environment by paracrine signalling. For this, we assessed the immunomodulatory capacity of conditioned medium from cultured ASCs (ASC-Cme) on high glucose (HG)-stimulated bovine retinal endothelial cells (BRECs).

Results ASCs augmented and stabilised retinal angiogenesis and co-localised with capillaries at a pericyte-specific position. This indicates that cultured ASCs exert juxtacrine signalling in retinal microvessels. ASC-Cme alleviated HG-induced oxidative stress and its subsequent upregulation of downstream targets in an NF- κ B dependent fashion in cultured BRECs. Functionally, monocyte adhesion to the monolayers of activated BRECs was also decreased by treatment with ASC-Cme and correlated with a decline in expression of adhesion-related genes such as *SELE*, *ICAM1* and *VCAM1*.

Conclusions/interpretation The ability of ASC-Cme to immunomodulate HG-challenged BRECs is related to the length of time for which ASCs were preconditioned in HG medium. Conditioned medium from ASCs that had been chronically exposed to HG medium was able to normalise the HG-challenged BRECs to normal glucose levels. In contrast, conditioned medium from ASCs that had been exposed to HG medium for a shorter time did not have this effect. Our results show that the manner of HG preconditioning of ASCs dictates their immunoregulatory properties and thus the potential outcome of treatment of diabetic retinopathy.

Keywords Adipose tissue-derived stromal cells · Diabetic retinopathy · High glucose · Oxidative stress

Abbreviations

ANGPT Angiotensinogen

ASC Adipose tissue-derived stromal cell

ASC-Cme Conditioned medium from ASCs

BREC Bovine retinal endothelial cell

CCL2 Chemokine (C-C motif) ligand 2

Ghazaleh Hajmoussa and Ewa Przybył contributed equally to this work.

✉ Martin C. Harmsen
m.c.harmsen@umcg.nl

¹ Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (EA11), 9713, GZ Groningen, the Netherlands

² 5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

³ Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

⁴ Department of Cell Biology, Molecular Imaging and Electron Microscopy, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

⁵ Ocular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

Research in context

What is already known about this subject?

- The immunomodulatory capacity of adipose tissue-derived stromal cells is relevant in cell therapy
- The aim is to use adipose tissue-derived stromal cells to reverse tissue dysfunction such as that caused by diabetes
- Pericyte dropout from retinal capillaries underlies diabetic retinopathy and subsequent aberrant angiogenesis

What is the key question?

- What is the influence of adipose tissue-derived stromal cells in the treatment of diabetic retinopathy?

What are the new findings?

- Adipose tissue-derived stromal cells augmented and stabilised retinal angiogenesis and co-localised with capillaries at a pericyte-specific position in a murine model of diabetic retinopathy
- Conditioned medium from adipose tissue-derived stromal cells alleviated high-glucose-induced oxidative stress and its subsequent upregulation of downstream targets in an NF- κ B-dependent fashion in bovine retinal endothelial cells
- The length of time for which adipose tissue-derived stromal cells are preconditioned in high glucose dictates their immunoregulatory properties

How might this impact on clinical practice in the foreseeable future?

- Our study endorses the medical translation of adipose tissue-derived stromal cell-based therapy for diabetic retinopathy

COX2	Cyclooxygenase-2
DCF	Dichlorofluorescein
DCFH-DA	2',7'-Dichlorofluorescein diacetate
HG	High glucose
LPS	Lipopolysaccharide
NAC	<i>N</i> -acetyl-L-cysteine
NG	Normal glucose
NO	Nitric oxide
NOTCH2	Neurogenic locus notch homolog protein 2
P	Postnatal day
PDR	Proliferative diabetic retinopathy
PGE2	Prostaglandin E ₂
PKC	Protein kinase C
qPCR	Quantitative real-time PCR
ROP	Retinopathy of prematurity
ROS	Reactive oxygen species
SEAP	Secreted embryonic alkaline phosphatase
VEGF	Vascular endothelial growth factor

Introduction

Diabetic retinopathy is the most common microvascular complication of diabetes and remains a leading cause of blindness worldwide [1]. The prevalence of diabetic retinopathy increases with diabetes duration and develops from non-proliferative diabetic retinopathy to proliferative diabetic retinopathy (PDR) and macular oedema [2]. Hyperglycaemia in the retina activates four main biochemical pathway-related changes: (1) polyol pathway

flux; (2) accumulation of advanced glycation end-products (AGEs); (3) activation of protein kinase C (PKC); (4) activation of hexosamine pathway flux [3]. Together, these molecular changes induce formation of reactive oxygen species (ROS), which induces impaired retinal blood flow and increased vascular permeability [4]. Retinas or vitreous from diabetic individuals with PDR contain increased levels of proinflammatory mediators including TNF- α , IL-1 β [5], IL-6 [6], IL-8 [7] and chemokine (C-C motif) ligand 2 (CCL2) [8, 9]. NF- κ B is the main transcription factor that regulates expression of proinflammatory genes. Activation and nuclear translocation of NF- κ B promotes forward feedback that augments the proinflammatory state of activated cells [10]. Diabetes is related to the upregulation of cyclooxygenase-2 (COX2) encoded by the prostaglandin-endoperoxide synthase 2 gene (*PTGS2*), both in macro- and microvessels [11]. In retinas of diabetic animals, increased COX2 is followed by increased production of prostaglandin E₂ (PGE₂) [12]. At the onset of diabetic retinopathy, pericyte dropout and the subsequent loss of retinal endothelial cells through apoptosis causes vasoregression. This is the driving force for the pathological angiogenesis of PDR [13]. In the normal retina, pericytes protect and regulate endothelial cell survival and proliferation, vessel integrity and the susceptibility of vascular cells to environmental stimuli [14]. Cell therapy with adipose tissue-derived stromal cells (ASCs) were promising in diabetic animal models. Adipose tissue is easy to acquire and is rich in ASCs. These ASCs are the endogenous mesenchymal stem cells in fat and they harbour a multipotent capacity to differentiate, for example, into adipocytes, chondrocytes and osteoblasts [15].

Recent studies suggested a direct role for ASCs in retinal microvascular support [16]. In rodent models of diabetic retinopathy, ASCs acquired pericytic features, which dampened proliferative angiogenesis [17, 18]. Recently, we showed that the pericytic nature of ASCs depends on neurogenic locus notch homolog protein 2 (NOTCH2)-based juxtacrine interaction between ASCs and endothelial cells [18]. Moreover, ASCs may home in on sites of inflammation [19]. The prime immunosuppressive factors produced by mesenchymal stem cells and ASCs include indoleamine 2,3-dioxygenase [20], PGE2 [21], nitric oxide (NO) [22], IL-10 [23] and antioxidant enzymes such as haem oxygenase-1 [24]. Individually or in combination, these factors also reduce oxidative stress in target cells [25, 26]. We hypothesised that ASCs preconditioned in high glucose (HG) can rescue a dysfunctional retinal endothelium through suppression of the inflammation that was caused by glucose-induced oxidative stress. The aim of this study was to investigate the immunomodulatory paracrine function of ASCs in decreasing the production of endothelial ROS and in the normalisation of dysfunctional endothelial cells in diabetic retinopathy.

Methods

Cell isolation and culture Human subcutaneous adipose tissue samples from healthy individuals (white females aged 25 to <75 years and BMI <30 kg/m²) were obtained after liposuction surgery (Bergman Clinics, Zwolle, the Netherlands). Anonymously donated samples were obtained with informed consent as approved by the ethical board of the University Medical Center Groningen, following the guidelines for ‘waste materials’. Lipoaspirates were enzymatically digested to obtain the ASCs, as described in our previous study [27]. The pooled ASCs from passages 3 to 6 were used for experiments. The ASCs were cultured in DMEM (Lonza, Basel, Switzerland) either with normal glucose (NG; 5 mmol/l D-glucose) or HG (30 mmol/l D-glucose) at normoxia (21% O₂). Continuous HG maintenance of ASCs (more than three passages; ≥21 days) was considered to be chronic HG, while short-term exposure to HG (7 days) was considered to be acute HG. Conditioned medium from ASCs (ASC-Cme) was collected from confluent monolayers after culturing for more than three passages in HG-DMEM. The percentage of FBS was reduced from 10% to 2% (vol./vol.) for 24 h prior to collection [28].

For the co-culture of ASCs and HUVECs, single-cell suspensions of HUVECs were seeded on top of confluent ASCs monolayers or, as a control, on gelatin-coated wells at 10,000 cells/cm² and vascular networks were allowed to form for at least 7 days [29]. Bovine retinal endothelial cells (BRECs) were isolated from freshly-enucleated cow eyes obtained from the slaughterhouse as described previously [30]. First-passage BRECs were used in all experiments. A purity of >99% was routinely achieved in BREC culture, which was checked

microscopically, and by immunofluorescence staining of von Willebrand factor (not shown). Confluent monolayers of BRECs were incubated in three different groups (NG-DMEM, HG-DMEM and ASC-Cme) for 7 days to study the effects of each set of conditions.

Ultrastructural analyses Co-cultures were fixed in 2% (wt/vol.) glutaraldehyde (Polysciences, Eppelheim, Germany) for 24 h. Samples were post-fixed using osmium tetroxide (Sigma-Aldrich, St. Louis, MO, USA)/potassium ferrocyanide (Sigma-Aldrich) for 30 min. Next, samples were embedded in Epon 812 (SERVA, Heidelberg, Germany) and polymerised at 37°C for 16 h followed by 56°C for 24 h. Thick sections (0.5 µm) were stained with toluidine blue (Sigma-Aldrich). Ultrathin sections (60 nm) were stained with uranyl-acetate (Sigma-Aldrich) in methanol and lead citrate (Sigma-Aldrich). Imaging was performed using a CM100 Biotwin transmission electron microscope (FEI, Eindhoven, the Netherlands).

Animals and the retinopathy of prematurity model All animal experiments in this study adhered to the association for research in vision and ophthalmology (ARVO) Statement for the use of animals in ophthalmic and vision research. Male C57BL/6J mice (Charles River, Frankfurt, Germany) were housed with free access to standard chow and water under a 12 h light-dark rhythm. To study the effect of ASCs on hypoxia-driven angiogenesis, newborn mice were subjected to the model of retinopathy of prematurity (ROP) [31]. Mice at postnatal (P) day 7 (P7) were exposed to an atmosphere of 75% oxygen with their nursing mother for 5 days and then returned to room air at P12. Directly after their return to room air, randomly selected mice were intravitreally injected under anaesthesia with either 1 µl of PBS containing approximately 10,000 ASCs (passage 1) or 1 µl of PBS as a control. Eyes were enucleated under deep anaesthesia at P13 for immunofluorescence analysis; at P13 and P19 for quantitative real-time PCR (qPCR) analysis; and at P17 for quantification of neovascularisation. After collection, eyes were immediately fixed in buffered formalin or stored at −80°C for the following analysis.

Quantification of hypoxia-driven neovascularisation Neovascularisation in retinas was assessed in paraffin sections of P17 animals injected at P12 with ASCs or a control. To this end, sections (6 µm) were stained with periodic acid–Schiff’s reagent (Sigma-Aldrich). Nuclei of neovessels at the vitreous side of the inner limiting membrane of the retinas were counted as described previously [32].

Assessment of ASCs in vivo

Whole-mount retinas from P13 animals were permeabilised with 0.5% (wt/vol.) Triton-X100 at room temperature for 1 h.

Overnight staining was with FITC/TRITC-labelled isolectin-B4 (1:50; Sigma-Aldrich) at 4°C. After PBS washes, retinas were flat-mounted in glycerol and micrographs were obtained with a fluorescence microscope (Lectin-FITC/ASC-Dil red staining; Leica BMR, Bensheim, Germany) or a confocal microscope (Lectin-TRITC/ASC-EGFP staining; Leica TCS SP2 confocal microscope, Leica, Wetzlar, Germany). ASCs presence was revealed through their pre-injection label, which was either CM-Dil-red (ThermoFisher, Waltham, MA, USA) or enhanced green fluorescent protein (EGFP) lentiviral tag.

Gene expression analysis Total RNA was extracted from ASCs and BRECs in TRIzol reagent (Life Technologies, Carlsbad, CA, USA) following the manufacturer's protocol. Retinas were isolated from frozen eyes of ROP and control mice at P13 ($n = 5$) and ROP mice at P19 in the presence of ASC injection or PBS ($n = 5$). Afterwards, 1 μg of total RNA from each sample was reverse transcribed using the First Strand cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania) according to the manufacturer's instructions. The cDNA equivalent of 10 ng RNA was used for amplification in 384-well plates in a TaqMan ABI 7900HT thermal cycler (Applied Biosystems, Foster City, CA, USA) in a final reaction volume of 10 μl containing 5 μl SYBR Green Universal PCR Master Mix (BioRad, Hercules, CA, USA) and 6 $\mu\text{mol/l}$ primer mix (forward and reverse). The cycle threshold (C_t) values were normalised to *GAPDH/ACTB* as a reference gene using the $\Delta\Delta C_t$ method [33].

Assessment of cell viability Viability was assessed using the Apoptosis & Necrosis Kit (Promokine, Heidelberg, Germany) as recommended in the manufacturer's instructions. In short, BRECs were incubated with 5 μl fluorescein-conjugated annexin V (a marker of apoptosis) and 5 μl ethidium homodimer III (at a concentration of 2×10^6 cells/ml) at room temperature for 15 min. Fluorescence was recorded on a BD FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA) within 1 h of staining.

Quantification of ROS Cellular ROS production was determined using the dye 2',7'-dichlorofluorescein diacetate (DCFH-DA, Sigma-Aldrich). Two-electron oxidation of DCFH-DA results in the formation of a fluorescent product, dichlorofluorescein (DCF) [34]. Experimental cells were suspended in 20 $\mu\text{mol/l}$ DCFH-DA in the dark at 37°C for 15 min. The general ROS scavenger *N*-acetyl-L-cysteine (NAC, 10 mmol/l, Sigma-Aldrich) and H_2O_2 (3 $\mu\text{mol/l}$, Merck Millipore, Darmstadt, Germany) were used as negative and positive controls, respectively. Samples were analysed directly using a FACSCalibur within 15 min of staining.

Screening for immune stimulation The supernatant of HG-stimulated BRECs cultured with or without ASC-Cme and the control group (BRECs in NG) were collected after 7 days. To

assess the immunogenicity of these samples, THP1-XBlue-MD2-CD14 cells (InvivoGen, Toulouse, France) were used as described previously [35]. THP1-XBlue-MD2-CD14 cells were plated, then each well was stimulated with samples of supernatants and cultured overnight at 37°C in 5% CO_2 . Lipopolysaccharide (LPS, 10 $\mu\text{g/ml}$, Sigma-Aldrich) was used as a positive control. Production of SEAP in the supernatant was quantified using QUANTI-Blue (InvivoGen). An aliquot of QUANTI-Blue (200 μl) was dispensed into a new flat-bottomed 96-well plate with 20 μl of supernatant from the stimulated cell-lines for 45 min at 37°C. Secreted embryonic alkaline phosphatase (SEAP) activity, representing activation of NF- κB , was then measured at a wavelength of 650 nm on a VersaMax microplate reader (Molecular Devices, Biberach an der Riss, Germany) [35].

ELISA Culture medium was collected from different experimental conditions. The concentrations of PGE2 and CCL2 in the medium were quantified, respectively, with the Prostaglandin E2 Human ELISA Kit (ThermoFisher) and the Human CCL2/MCP-1 DuoSet ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol. LPS (200 ng/ml) and TNF- α (50 ng/ml, Sigma-Aldrich) were used as positive controls. The COX2 inhibitor celecoxib (10 mmol/l, Sigma-Aldrich) was used to inhibit PGE2 production. Results were normalised to the number of cells in each experimental condition and presented in pg/ml as fold change relative to their respective experimental controls.

Monocyte adhesion assay One of the cardinal steps of inflammation is the infiltration of immune cells such as monocytes across the endothelial cell layer [36]. THP-1 monocytes were stained using the Vybrant CFDA SE Cell Tracer Kit (ThermoFisher) according to the manufacturer's instructions. Treated groups of BRECs (under HG with or without ASC-Cme), a positive-control group (pre-incubated with medium containing TNF- α [10 ng/ml] for 8 h) and a control group (NG) were plated at a density of 5×10^3 cells/cm² in standard 96-well culture plates and allowed to adhere at 37°C for 4 h. Labelled THP-1 cells (2×10^5 cells/ml) were added to each well. After incubation for 1 h, wells were washed to remove non-adhered cells. Fluorescence of adherent cells was recorded on a Varioskan spectrofluorometer (Thermo Scientific, Waltham, MA, USA) at excitation/emission = 492/520 nm [37].

Scratch wound healing assay BRECs in three different groups (NG, HG and ASC-Cme) were cultured until they reached confluency. The straight, width-limited scratch was made in all the wells, simulating a wound. The recovery of both wound edges was recorded simultaneously using the Solamere Nipkow confocal live cell imaging microscope (Solamere Technology Group, Salt Lake City, UT, USA) for 30 h. The

percentage of covered area between the edges was analysed by ImageJ 1.8.0-172 software (imagej.nih.gov/ij/download/).

Statistical analysis Data are expressed as mean \pm SEM and relative to vehicle controls of at least three independent experiments in triplicate. Statistical evaluation was performed using unpaired *t* tests and ANOVA followed by Bonferroni post hoc analysis. *p* values <0.05 were considered statistically significant.

Results

Ultrastructure of ASC-induced vascular networks The 0.5 μm cross-sections showed that interconnected laminar structures

had been formed by co-cultures of endothelial cells on ASC monolayers at day 5 and subsequent days (Fig. 1a). Transmission electron micrographs of longitudinal sections showed the build-up of 3D structures that comprised endothelial-cell-derived (Fig. 1c) vessel-like structures with a lumen (Fig. 1a–c), surrounded and tightly aligned by ASCs (Fig. 1c). At high magnification, these vessel-like structures appeared as intermittent structures between the ASCs (Fig. 1d). The vascular networks formed were reminiscent of genuine vessels with respect to the slanted intercellular junctions between endothelial cells (Fig. 1e, h, i). Peg-and-socket processes [38, 39] that extended from ASC-derived pericytes to endothelial cells had also formed (Fig. 1f, g), as well as an extracellular matrix-based membrane between pericytes and




Fig. 1 Ultrastructure of ASC-induced vascular network. HUVECs were seeded on confluent monolayers of ASCs. After 5 days, 0.5 μm sections were stained with toluidine blue and analysed by light microscopy, and 60 nm sections of glutaraldehyde-fixed and plastic-embedded co-cultures were analysed by transmission electron microscopy. (a–c) Representative light micrographs: (a) Planar, parallel section (i.e. the top view of the culture) showing the formation of a vascular network (arrows, endothelial cells) demarcated by the dotted lines. Lumens (L) have formed, which are aligned by ASCs (black arrowheads) in close contact. (b) Cross section of the lumen-containing 3D vascular structures in between (interrupted) layers of ASCs. (c) Enlargement of a vascular structure with several aligned ASCs (arrows, endothelial cells; black arrowheads, ASCs). (d–i) Transmission electron micrographs of the vascular structures: (d) a vascular structure consisting of endothelial cells (arrows) and lumen is depicted by the dotted lines with surrounding ASCs (black arrowheads).

(e) Specific cell–cell connections with tight junctions between endothelial cells (white arrowheads), with lumen formation on top of the ASCs. (f) ASCs deposit extracellular matrix (black asterisks), which forms a base-membrane-like structure between the endothelial cells and the ASCs. (f, g) Peg-and-socket connections are shown by the lightning symbols, and the inset in (g) shows intracellular filaments (white asterisks), indicative of contractility, similar to smooth muscle cells, i.e. hinting at the maturation of ASCs to pericytes. (h, i) Detailed views of the endothelial cell–cell connections and basal membrane formation around the endothelial cells, i.e. the vascular structure with connected ASCs. Scale bar, 5 μm . Lumen (L); endothelial cells (arrows); ASCs (black arrowheads); endothelial cell–cell connections (white arrowheads); extracellular matrix formation (black asterisks); intracellular filaments representative for smooth muscle cell phenotype (white asterisks); peg-and-socket connections of ASCs with endothelial cells (lightning symbols)

endothelial cells (Fig. 1f, i). ASC-derived pericytes, i.e. those cells in close contact with endothelial cells, had lost their typically abundant vesicular contents compared with more distal ASCs (Fig. 1d). These ultrastructural results indicate that ASCs promoted formation of vascular networks by endothelial cells and that ASCs had acquired a functional pericytic phenotype in vitro (Fig. 1g).

ASCs stabilise hypoxia-driven angiogenesis but also engraft at pericytic sites in the animal model of ROP ASCs were injected intravitreally at P12 in the eyes of ROP-model mice (Fig. 2a). At P13, injected ASCs were present in angiogenic sprouts and had attached to endothelial cells of maturing capillaries at a pericyte-like position (arrows, Fig. 2b, c). Further analyses showed that dye-labelled-ASCs (green, Fig. 2d–f) had aligned and attached to maturing intraretinal capillaries (red, Fig. 2d–f) at pericyte-specific perivascular positions and in contact with the endothelium.

Quantification of hypoxia-induced retinal neovascularisation at P17 showed that injection of ASCs in the animal models of ROP increased neovascularisation by 54% (Fig. 2g–i; PBS vs ASCs, 8.3 ± 0.62 vs 12.8 ± 0.96).

ASCs modulate the inflamed ROP micro-environment ROP and control retinas (P13) were assessed by qPCR. At P13, i.e. 24 h after returning the animals from hyperoxia to ambient oxygen, *Angpt1* (encoding angiopoietin [ANGPT] 1) expression had slightly decreased in ROP retinas, while *Angpt2* had slightly increased (although neither significantly) compared with the non-ROP controls (Fig. 3a). This was accompanied by increased expression of angiogenesis-related genes i.e. *Vegfa* (encoding vascular endothelial growth factor [VEGF] A; 2.0-fold change), *Fgf2* (3.2-fold change), and *Col4a1* (1.4-fold change) (Fig. 3a). The analysis showed increased expression of proinflammatory genes i.e. *Il1b* (2.0-fold change) and *Ccl2* (2.1-fold change) compared with P13 controls. *Cxcl15* (mouse orthologue of human *CXCL8*) and *Tnf* changed non-significantly (Fig. 3a). Comparison of ROP retinas with and without ASC intervention showed that injection of ASCs at P12 caused a 1.5-fold increase of *Angpt1* and a 0.6-fold decrease of *Angpt2*, suggesting induction of vascular quiescence. Injection of ASCs into the ROP eyes caused increased expression of inflammatory genes such as *Tnf*, *Cxcl15* and *Ccl2* by 2.2-, 1.8- and 2.5-fold, respectively. A slight decrease was observed in the expression of proangiogenic *Vegfa* and a 1.3-fold increase of *Fgf2* was observed in ROP at P19 with ASCs, compared with the control ROP at P19 without ASCs (Fig. 3b). No differences in the expression of *Pdgfb*, *Col4a1* and *Il1b* were detected.

Chronic or acute exposure to HG influences ASC gene expression The expression of 36 relevant genes was measured in ASCs after acute exposure to HG (i.e. maintained in NG medium, followed by 7 days in HG medium) or chronic exposure to HG

(i.e. always maintained in HG medium and for more than 21 days). Data are presented as the fold change compared with (chronic) maintenance in NG medium (Fig. 4a, b). The acute exposure of ASCs to HG upregulated the proinflammatory genes *TNF* (1.8-fold change), *IL1A* (6.0-fold change), *IL6* (4.5-fold change), *CCL2* (4.3-fold change) and *CXCL8* (6.0-fold change); as well as the proangiogenic genes *VEGFA* (4.8-fold change), *ANGPT2* (1.8-fold change) and *MMP1* (4.2-fold change). Expression of the angiopoietin receptors *TIE1* and *TEK* (also known as *TIE2*) was downregulated (0.52-fold and 0.47-fold change, respectively). The glucose transporter *SLC2A1* (encoding GLUT1) was upregulated 2.5-fold. Interestingly, acute HG exposure induced a 4.9-fold change in the mesenchymal pericyte marker *RGS5*, while expression of other mesenchymal markers such as *ACTA1*, *TAGLN* and *PDGFRB* changed only marginally. Endothelial marker *PECAMI1* was also upregulated (1.3-fold change). The expression of two immunoregulatory genes, *PTGS2* (encoding COX2) and *IDO1*, were upregulated (3.4-fold and 3.6-fold change, respectively). The expression of all genes in ASCs was similar upon culture under chronic HG and chronic NG conditions, which indicated that ASCs adapt to different glucose concentrations in the culture medium during long-term culture. The inflammatory response after acute exposure to HG resulted in an increased release of PGE2 (11.0-fold change) and *CCL2* (1.6-fold change) by ASCs, compared with chronic exposure to HG (Fig. 4c, d). Interestingly, chronic exposure to HG medium slightly decreased PGE2 secretion (0.3-fold change) and secretion of *CCL2* (0.8-fold change) compared with controls maintained in NG. LPS and TNF- α both induced the secretion of PGE2 and *CCL2*, while celecoxib inhibited the production of PGE2 completely and had less effect on secretion of *CCL2* in acute-HG-stimulated ASCs.

The antioxidant role of ASC-Cme abrogates NF- κ B activation and promotes cell viability of BRECs Culture of BRECs under HG conditions for 7 days induced cell death (viability \sim 88% vs 94.6% for HG vs NG, Fig. 5a). Apoptosis was increased (annexin V-positive cells \sim 11.2% vs 4.6% for HG vs NG, Fig. 5b), while necrosis had also increased (ethidium homodimer III-positive cells \sim 0.73% vs 0.45% for HG vs NG, Fig. 5c). Simultaneous treatment of HG-stimulated BRECs with ASC-Cme (i.e. conditioned medium from ASCs chronically cultured in HG medium) normalised viability (\sim 93.9% vs 88% for ASC-Cme vs HG, Fig. 5a) and suppressed apoptosis (\sim 4.8% vs 11.2% for ASC-Cme vs HG, Fig. 5b) and necrosis (\sim 0.25% vs 0.73% for ASC-Cme vs HG, Fig. 5c) of the BRECs.

Exposure of BRECs to HG increased intracellular ROS production (4.6-fold change compared with NG controls, Fig. 5e), while ASC-Cme abrogated this (0.4-fold change, Fig. 5e). This was comparable to the NAC effect on HG-induced BRECs (0.25-fold change, Fig. 5e).

The monocytic NF- κ B reporter (SEAP) cell line THP1-XBlue-MD2-CD14 was used to assess the proinflammatory




Fig. 2 ASCs enhance hypoxia-driven angiogenesis in the ROP mouse model. **(a)** Scheme of the ROP model. Mouse pups were exposed to hyperoxia (75% O₂) from P7 to P12 and subsequently transferred to room air (21% O₂). This causes hypoxia at room air that results in extensive retinal neovascularisation at P17. ASCs were injected into the vitreous at P12 to evaluate their influence on hypoxia-driven neovascularisation. **(b, c)** Representative micrographs of CM-DiI-labelled ASCs (red, white arrows) co-localising with the endothelial layer (lectin, green); magnification $\times 20$. **(d–f)** Micrographs of EGFP-tagged ASCs (green) co-localising with the endothelial layer (lectin, red) in the pericytic position. The scale bars in **(d–f)** are 100 μ m, 25 μ m and 15 μ m, respectively. **(g, h)** Histological analysis of the effects of ASC injection on hypoxia-induced retinal neovascularisation; magnification $\times 20$. Neovascularisation was

assessed histologically by counting the endothelial cell nuclei anterior to the inner limiting membrane. **(g)** Histological features of retinal neovascularisation in the control group. **(h)** Histological features of retinal neovascularisation in ASC-injected mice. Intravitreal injection of ASCs in the ROP mouse model increased the number of neovascular tufts extending into the vitreous (black arrows). **(i)** Hypoxia-driven neovascularisation in the retinas was enhanced by 54% in animals injected with ASCs (PBS vs ASC, 8.3 ± 0.62 vs 12.8 ± 0.96). The graph shows the mean number of neovascularisation nuclei per section per animal, *** $p < 0.001$. GCL, ganglion cell layer; ILM, inner limiting membrane; INL, inner nuclear layer; neovascul., neovascularised; ONL, outer nuclear layer

capacity of conditioned medium obtained from BRECs that were co-treated with HG and ASC-Cme. The strongest

activation of NF- κ B occurred after stimulation with LPS (29.0-fold change, Fig. 5f), while neither NG nor HG medium




Fig. 3 ASCs modulate the ROP micro-environment. Gene expression analyses normalised to *Gapdh* of (a) dissected ROP retinas at P13 (grey bars) compared with the control retinas at P13 (white bars). The expression levels of *Vegfa*, *Fgf2*, and *Col4a1* were increased. In addition, an inflammatory response was induced, as measured by increased expression of *Il1b* and *Ccl2*. (b) To assess the ASC-guided changes to the ROP micro-environment at P19, gene expression in ROP retinas of eyes with ASC injection (grey bars) were compared with controls (white bars). We

observed increased expression of *Angpt1* and *Fgf2*, and decreased expression of *Angpt2* in ROP retinas of eyes with ASC injection. The expression of *Vegfa*, *Pdgfb* and *Col4a1* was similar to controls. The inflammatory response was modulated by normalised *Il1b* expression, while the expression of *Tnf*, *Cxcl15* and *Ccl2* was increased. * $p < 0.05$, ** $p < 0.01$ vs control retinas. Graphs show the means \pm SEM from retinas of five animals in each group; experiments were performed in triplicate

(DMEM) had any influence. Compared with NG controls, the activation of monocyte-expressed NF- κ B increased (1.4-fold change) upon exposure to conditioned medium from HG-stimulated BRECs. In contrast, NF- κ B activation was normalised to NG control levels (0.6-fold change) by conditioned medium from BRECs that were HG induced and simultaneously treated with ASC-Cme.

ASC-Cme downregulates principal inflammatory factors in HG-challenged BRECs HG stimulation of BRECs for 7 days upregulated the gene expression of the relevant proinflammatory genes *TNF*, *IL1B*, *IL1A*, *IL6*, *CXCL8* and *CCL2*, as well as leucocyte adhesion-related genes *SELE*, *ICAM1* and *VCAM1*. In addition, the proangiogenic genes *ANGPT1*, *ANGPT2*, *VEGFA*, *VEGFB* and *PDGFB*, and the endothelial NO synthases, *NOS2* and *NOS3*, were upregulated, as well as *PTGS2*. The upregulation of these genes was normalised to

NG control level in ASC-Cme-treated HG-challenged BRECs. Only *KLF4* did not change after HG challenge of BRECs. Interestingly, expression of both *KLF4* and *NOS2* were upregulated in ASC-Cme-treated HG-challenged BRECs. The expression of *ANGPT1*, a vessel quiescence-associated factor, remained increased upon ASC-Cme treatment of HG-challenged BRECs (Fig. 6a–r).

As expected, the proinflammatory condition of HG-challenged BRECs (Fig. 6a–r) also increased their adhesiveness to THP-1 monocytes (2.4-fold change, Fig. 7a), while treatment with ASC-Cme normalised monocytic adhesion to NG levels (0.6-fold change). Treatment of BRECs with TNF- α promoted the strongest adhesion of monocytes (4.5-fold change, Fig. 7a).

Wound closure of BRECs cultured in NG medium, after HG challenge or treatment with ASC-Cme during HG challenge, was similar over a measurement period of 30 h, after which time full closure occurred (Fig. 7b).




Fig. 4 Anti-inflammatory and anti-apoptotic effects of ASCs depend on chronic HG preconditioning. **(a, b)** Expression of 36 genes, normalised to *ACTB*, in ASCs after acute exposure to HG (7 days) or chronic HG (more than 21 days maintenance in HG) compared with NG-exposed controls. Grey bars, acute HG exposure; white bars, chronic HG exposure. Graphs represent data ± SEM from *n* = 4 independent experiments. **p* < 0.05, ***p* < 0.01, ****p* < 0.001 vs NG-exposed control. **(c, d)** The inflammatory response in HG conditions was induced in ASCs and measured by ELISA to detect PGE2 and CCL2 in ASC-Cme. LPS and TNF-α were used as positive-stimulated controls. Celecoxib (10 mmol/l) was used as an inhibitor of COX2 in acute-HG-treated ASCs. Graphs show mean ± SEM from *n* = 5 independent experiments. **p* < 0.05, ***p* < 0.01, ****p* < 0.001 vs NG control; ††*p* < 0.01, †††*p* < 0.001 vs chronic HG. Genes encode the following proteins: *TNF*, tumour necrosis factor; *IL1B*, IL-1β; *IL1A*, IL-1α; *IL6*, IL-6; *CXCL8*, C-X-C motif chemokine ligand 8 (also known as IL-8); *CCL2*, chemokine (C-C motif) ligand 2; *PTGS2*, prostaglandin-endoperoxide synthase 2; *CXCL12*, C-X-C motif

chemokine 12; *NFKB1*, NF-κB subunit 1; *MMP1*, matrix metalloproteinase 1; *ICAM1*, intercellular adhesion molecule 1; *IDO1*, indoleamine 2,3-dioxygenase 1; *IL1R1*, IL-1 receptor type 1; *IL1RN*, IL-1 receptor antagonist; *IL10RA*, IL-10 receptor subunit α; *IL10RB*, IL-10 receptor subunit β; *SLC2A1*, solute carrier family 2 member 1 (also known as GLUT1); *SLC2A4*, solute carrier family 2 member 4 (also known as GLUT4); *VEGFA*, vascular endothelial growth factor A; *KDR*, kinase insert domain receptor/VEGF receptor 2; *TGFB1*, TGF-β1; *FGF2*, fibroblast growth factor 2; *IGF*, IGF; *ANGPT1*, angiotensin 1; *ANGPT2*, angiotensin 2; *TIE1*, tyrosine kinase with immunoglobulin like and EGF like domains 1; *TEK*, TEK receptor tyrosine kinase (also known as Tie2); *PDGFRB*, platelet derived growth factor receptor β; *RGS5*, regulator of G-protein signalling 5; *TAGLN*, transgelin; *ACTA1*, actin α1; *PECAM1*, platelet/endothelial cell adhesion molecule 1 (skeletal muscle); *CNN1*, calponin 1; *MCAM*, melanoma cell adhesion molecule (also known as CD146); *DES*, desmin; *THY1*, Thy-1 cell surface antigen (also known as CD90)




Fig. 5 The antioxidant role of ASC-Cme, combined with declining NF- κ B activation, promotes cell viability of HG-challenged BRECs. **(a)** ASC-Cme promotes BREC viability following HG-induced apoptosis (viability ~88% vs 94.6%, HG vs NG; 88% vs 93.9%, HG vs Cme). **(b)** HG-induced apoptosis was normalised by ASC-Cme (annexin V-positive cells ~11.2% vs 4.6%, HG vs NG; 11.2% vs 4.8%, HG vs Cme). **(c)** Necrosis (ethidium [ET] homodimer III-positive cells ~0.73% vs 0.45%, HG vs NG; 0.73% vs 0.25% HG vs Cme). **(a–c)** LPS was used as a positive control. **(d)** The histogram shows the representative increase of fluorescence intensity (by DCF) after exposure to HG or H₂O₂ control compared with NG or ASC-Cme and NAC treatment. **(e)** HG induces ROS in BRECs. Total cellular ROS production was measured by DCF. ASC-Cme suppressed ROS production in the presence of HG, compared with HG alone. The ROS inhibitor NAC and H₂O₂ were used as negative

and positive controls, respectively. **(f)** NF- κ B activation by conditioned BREC medium in THP1-XBlue-MD2-CD14 cells, and mediated by ASC-Cme. NF- κ B activation was significantly higher in cells treated with BREC conditioned medium under HG conditions (BREC under HG), compared with unstimulated control. This response was almost absent when cells were treated with ASC-Cme alongside BREC conditioned medium under HG conditions (BREC under Cme). LPS was used as a positive control for THP1-XBlue-MD2-CD14 cells and induced NF- κ B activation. RPMI-1640 medium, NG-DMEM and HG-DMEM were used as controls, which had no effect on activation of THP1-XBlue-MD2-CD14 cells. Absorbance values were plotted to express NF- κ B activation with arbitrary units. * p < 0.05, ** p < 0.01, *** p < 0.001 vs NG control; † p < 0.05, †† p < 0.01, ††† p < 0.001 vs HG. Values are mean \pm SEM (n = 4 in **a–c**, **f** and n = 5 in **e**). Cme, ASC-Cme

Discussion

The main results of our studies are that human ASCs stimulate retinal angiogenesis in ROP mice via acquisition of a

pericytic position and function. This was confirmed by ultrastructural analyses showing that in vitro ASCs promote vascular network formation of endothelial cells and stabilise these networks via a pericytic function. Extracellular matrix




Fig. 6 ASC-Cme downmodulates the main inflammatory genes in HG-challenged BRECs, compared with NG-treated controls. **(a–r)** HG up-regulated the expression of the main genes related to inflammation (excluding *KLF4*, **n**). The upregulation of *TNF*, *IL1B*, *IL1A*, *IL6*, *CXCL8*, *VCAM1*, *SELE*, *ICAM1*, *VEGFA*, *VEGFB*, *PDGFB*, *CCL2*, *PTGS2*, and

NOS3 was significantly modulated (reduced) by ASC-Cme. ASC-Cme upregulated the gene expression of *ANGPT1*, *KLF4* and *NOS2*. Values are mean ± SEM ($n = 6$). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs NG control; † $p < 0.05$, †† $p < 0.01$ vs HG

was deposited between ASC-derived pericytes and endothelial cells in vitro, while typical peg-and-socket connections were also formed [38, 39]. Acute exposure of ASCs to HG caused a proinflammatory and proangiogenic activation

compared with ASCs that were propagated chronically in HG. In fact, conditioned medium from ASCs that had been chronically exposed to HG reduced ROS and proinflammatory activation of BREC cells challenged with HG. Activated




Fig. 7 (a) THP-1 cell adhesion to BRECs exposed to HG, with and without ASC-Cme. The intensity of fluorescence of adherent THP-1 cells (mean \pm SEM, $n=3$, fold change of NG-treated control) in resting or activated BRECs was measured. A significant decrease in adhered THP-1 cells occurred after treatment of HG-challenged BRECs with ASC-Cme, compared with HG treatment alone. (b) Scratch wound healing assay to study interaction in the BREC monolayer under NG, HG and ASC-Cme conditions. The percentage of covered area between the wound edges was analysed. The percentage signifies the remaining gap size 30 h after making the scratches, compared with the initial gap size. The gap width decreased in a similar pattern in all three groups (NG, closed circles; HG, open circles; ASC-Cme, open diamond) and was not significantly delayed in HG conditions. Values are mean \pm SEM. ** $p < 0.01$, *** $p < 0.001$ vs NG control; † $p < 0.05$ vs HG

genes were reduced to normal expression levels, while endothelial protective genes such as *KLF4* were upregulated. The immunomodulatory properties of ASCs [40–42] may vary upon passaging in culture [41]. Early passages of ASCs express markers, e.g. ligands that stimulate cells of the adaptive immune system such as MHCII, CD80 and CD86, which are lost upon passaging [41, 43]. Our results show that ASC injection into ROP mice, a model of pathological angiogenesis in PDR [44], led to an increased expression of inflammatory genes such as *Tnf*, *Cxcl15* and *Ccl2*, which might relate to the early passaging of ASCs. The balance of *ANGPT1* and *ANGPT2* and the expression of *VEGFA* are among the most important regulators of vascular development, maturation and maintenance [45]. Reduced expression of pericyte-derived *ANGPT1*, and concomitant upregulation of its antagonist *ANGPT2* and increased *VEGFA* levels induce pericyte dropout, vessel destabilisation and sprouting angiogenesis [46]. In ROP retinas of ASC-treated mice, expression of *Angpt1* and

Fgf2 were increased, while levels of *Angpt2* and *Vegfa* were reduced. Injected ASCs adhered to neovessels at a pericytic position. This corroborates the role of *NOTCH2* in the juxtacrine function of ASCs [18]. Earlier work from our group showed that under acute HG culturing, ASCs largely maintain their pericytic role as an endothelial supporting cell, despite an upregulated ROS production accompanied by increased apoptosis in ASCs [29].

In general, most papers use DMEM as constitutive culture medium to propagate ASCs. This medium contains 25 mmol/l D-glucose, which is, in fact, similar to hyperglycaemic conditions in vivo. A main finding of our study was that chronic exposure of ASCs to HG medium normalised gene expression to levels seen under NG conditions. Interestingly, in comparison to chronic propagation in HG, ASCs that were shifted from NG-DMEM to HG-DMEM for 7 days had upregulated gene expression of proinflammatory cytokines and chemokines, but also of proangiogenic factors. Moreover, secretion of PGE2 and CCL2 were also strongly increased. COX2 is responsible for the diabetes-induced retinal PGE2 production, and inhibition of COX2 inhibited the diabetes-induced upregulation of retinal VEGF, which links COX2 expression to angiogenesis in diabetic retinopathy [12, 47, 48]. PGE2 activates the extracellular signal-regulated kinases 1 and 2 (ERK1/2) and thus promotes angiogenesis through endothelial upregulation of the secretion of e.g. VEGF, chemokines and activation of cell cycle genes [49, 50]. Thus, the acute HG exposure of ASCs likely renders these cells in a proangiogenic state. Their upregulated expression of proinflammatory genes likely also activates endothelial cells. Yet the exposure of retinal endothelial cells to HG alone activated NF- κ B and increased expression of downstream *IL1B*, *VEGFA*, *TNF* and *ICAM1* to name a few of the upregulated main proinflammatory genes. ASC-Cme suppressed these proinflammatory genes such as *PTGS2* in BRECs plus *VEGFA* as a proangiogenic gene. Acute HG exposure of ASCs would induce endothelial dysfunction rather than counteract it. However, the continuous propagation of ASCs in HG medium not only suppresses their proinflammatory status, but also augments their capacity to normalise endothelial cell function. This was corroborated in HG-activated BRECs by the suppression, by ASC-Cme, of ROS production, the reduction of monocyte adhesion and improved cell survival (Fig. 8). Part of the immunosuppression resides in the suppression of endothelial ROS production by ASC-secreted factors, because ROS functions, via activation of TAK1, as an activator of NF- κ B. Taken together, our results show that HG preconditioning of ASCs potentially improves their therapeutic efficacy as compared with short-term exposure to environmental conditions such as HG.




Fig. 8 Therapeutic actions of ASCs in the normalisation of HG-challenged BRECs: a roadmap to the treatment of diabetic retinopathy. **(a)** BRECS under HG conditions and **(b)** with the addition of ASC-Cme. This model was corroborated in HG-activated BRECs by the suppression of ROS production by ASC-Cme, together with a reduction in monocyte adhesion and improved cell survival. ASCs preconditioned in HG can

rescue dysfunctional retinal endothelium through suppression of the inflammatory and proangiogenic genes induced by glucose-induced oxidative stress, and can stabilise their vascular networks via pericytic function. EC, endothelial cell; ICAM1, intercellular adhesion molecule 1; PS, phosphatidylserine; SELE, selectin E; VCAM1, vascular cell adhesion molecule

Acknowledgements The authors gratefully acknowledge the help and assistance of P. Bugert, N. Dietrich and V. Schwarz from the 5th Medical Department, University of Heidelberg, Germany; and J. Dokter-Fokkens and K. Sjollem from the Faculty of Medical Science, University of Groningen, the Netherlands.

Data availability Data supporting the conclusions of this article are included within the article and are available from the corresponding author on reasonable request.

Funding This study was supported by grants of the Translational excellence in Regenerative Medicine (TeRM) SmartMix Program of the Netherlands Ministry of Economic Affairs and the Netherlands Ministry of Education, Culture and Science and from the Deutsche Forschungsgemeinschaft (DFG): international research training group (GRK 880 Vascular Medicine, and GRK1874 DIAMICOM Mannheim, Germany).

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement GH designed the study, acquired data, analysed/interpreted data, wrote and revised the manuscript. EP, FP, SB and JK designed the study, acquired data, analysed/interpreted data and reviewed/revise the in vivo part of the manuscript. GAPJ and KM designed the study, acquired data, analysed/interpreted data and reviewed/revise the in vitro part of the manuscript. IK, MJAvL, GK, HPH and MCH designed the study and reviewed/revise the manuscript. All authors are fully responsible for all content and editorial decisions and were involved at all stages of manuscript development, and have approved the final version of the manuscript to be published. MCH is responsible for the integrity of the work as a whole.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Fong DS, Cavallerano JD, Aiello L et al (2003) Diabetic retinopathy. *Diabetes Care* 26:226–229
- Kempner JH, O'Colman BJ, Leske C et al (2004) The prevalence of diabetic retinopathy among adults in the United States. *Arch Ophthalmol* 122:552–563
- Brownlee M (2005) The pathobiology of diabetic complications - a unifying mechanism. *Diabetes* 54:1615–1625
- Chen Y, Hu Y, Moiseyev G, Zhou KK, Chen DY, Ma JX (2009) Photoreceptor degeneration and retinal inflammation induced by very low-density lipoprotein receptor deficiency. *Microvasc Res* 78:119–127
- Demircan N, Safran BG, Soyulu M, Ozcan AA, Sizmaz S (2006) Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. *Eye* 20:1366–1369
- Abu el Asrar AM, Maimone D, Morse PH, Gregory S, Reder AT (1992) Cytokines in the vitreous of patients with proliferative diabetic retinopathy. *Am J Ophthalmol* 114:731–736
- Elnor SG, Elnor VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM (1995) Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. *Curr Eye Res* 14:1045–1053
- Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J (2006) Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. *Eur Cytokine Netw* 17:155–165
- Abu el-Asrar AM, Van Damme J, Put W et al (1997) Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. *Am J Ophthalmol* 123:599–606
- Kern TS (2007) Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. *Exp Diabetes Res*. <https://doi.org/10.1155/2007/95103>
- Szerafin T, Erdei N, Fulop T et al (2006) Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arteries of patients with diabetes mellitus. *Circ Res* 99:E12–E17
- Ayalasomayajula SP, Amrite AC, Kompella UB (2004) Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E-2 secretion from diabetic rat retinas. *Eur J Pharmacol* 498:275–278
- Hammes HP, Feng YX, Pfister F, Brownlee M (2011) Diabetic retinopathy: targeting vasoregression. *Diabetes* 60:9–16
- Armulik A, Abramsson A, Betsholtz C (2005) Endothelial/pericyte interactions. *Circ Res* 97:512–523
- Gimble JM, Guilak F (2003) Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. *Cytotherapy* 5:362–369
- Rajashekhar G, Ramadan A, Abburi C et al (2014) Regenerative therapeutic potential of adipose stromal cells in early stage diabetic retinopathy. *PLoS One* 9:e84671
- Mendel TA, Clabough EBD, Kao DS et al (2013) Pericytes derived from adipose-derived stem cells protect against retinal vasculopathy. *PLoS One* 8:e65691
- Terlizzi V, Kolibabka M, Burgess JK, Hammes HP, Harmsen MC (2018) The pericytic phenotype of adipose tissue-derived stromal cells is promoted by NOTCH2. *Stem Cells* 36:240–251
- Fiori A, Terlizzi V, Kremer H et al (2018) Mesenchymal stromal/stem cells as potential therapy in diabetic retinopathy. *Immunobiology*. <https://doi.org/10.1016/j.imbio.2018.01.001>
- DelaRosa O, Lombardo E, Beraza A et al (2009) Requirement of IFN- γ -mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. *Tissue Eng A* 15:2795–2806
- Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 105:1815–1822
- Ren GW, Zhang LY, Zhao X et al (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. *Cell Stem Cell* 2:141–150
- Gao F, Wu DQ, Hu YH et al (2008) In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. *Transl Res* 151:293–302
- Chabannes D, Hill M, Merieau E et al (2007) A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. *Blood* 110:3691–3694
- Kadekar D, Rangole S, Kale V, Limaye L (2016) Conditioned medium from placental mesenchymal stem cells reduces oxidative stress during the cryopreservation of ex vivo expanded umbilical cord blood cells. *PLoS One* 11:e0165466
- Li MR, Zhao YL, Hao HJ et al (2015) Mesenchymal stem cell-conditioned medium improves the proliferation and migration of keratinocytes in a diabetes-like microenvironment. *Int J Lower Extrem Wounds* 14:73–86
- Hajmoussa G, Vogelaar P, Brouwer LA, van der Graaf AC, Henning RH, Krenning G (2017) The 6-chromanol derivative SUL-109 enables prolonged hypothermic storage of adipose tissue-derived stem cells. *Biomaterials* 119:43–52

28. Iwashima S, Ozaki T, Maruyama S et al (2009) Novel culture system of mesenchymal stromal cells from human subcutaneous adipose tissue. *Stem Cells Dev* 18:533–543
29. Hajmoussa G, Elorza AA, Nies VJM, Jensen EL, Nagy RA, Harnsen MC (2016) Hyperglycemia induces bioenergetic changes in adipose-derived stromal cells while their pericytic function is retained. *Stem Cells Dev* 25:1444–1453
30. Wisniewska-Kruk J, Hoeben KA, Vogels IMC et al (2012) A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes. *Exp Eye Res* 96:181–190
31. Smith LEH, Wesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 35:101–111
32. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT (1996) Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. *Nat Med* 2:529–533
33. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C_t}$ method. *Methods* 25:402–408
34. Eruslanov E, Kusmartsev S (2010) Identification of ROS using oxidized DCFDA and flow-cytometry. *Methods Mol Biol* 594:57–72
35. Paredes-Juarez GA, Sahasrabudhe NM, Tjoelker RS et al (2015) DAMP production by human islets under low oxygen and nutrients in the presence or absence of an immunisolating-capsule and necrostatin-1. *Sci Rep* 5:14623
36. Ortega-Gomez A, Perretti M, Soehnlein O (2013) Resolution of inflammation: an integrated view. *EMBO Mol Med* 5:661–674
37. Dicolorleto PE, Delamotte CA (1985) Characterization of the adhesion of the human monocytic cell-line U937 to cultured endothelial-cells. *J Clin Investig* 75:1153–1161
38. Caruso RA, Fedele F, Finocchiaro G et al (2009) Ultrastructural descriptions of pericyte/endothelium peg-socket interdigitations in the microvasculature of human gastric carcinomas. *Anticancer Res* 29:449–453
39. Diaz-Flores L Jr, Gutierrez R, Madrid JF et al (2011) Peg-and-socket junctions between smooth muscle cells and endothelial cells in femoral veins are stimulated to angiogenesis by prostaglandin E(2) and glycerols. *Histol Histopathol* 26:623–630
40. Keyser KA, Beagles KE, Kiem HP (2007) Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. *Cell Transplant* 16:555–562
41. McIntosh K, Zvonic S, Garrett S et al (2006) The immunogenicity of human adipose-derived cells: temporal changes in vitro. *Stem Cells* 24:1246–1253
42. Yoo KH, Jang IK, Lee MW et al (2009) Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. *Cell Immunol* 259:150–156
43. Lindroos B, Suuronen R, Miettinen S (2011) The potential of adipose stem cells in regenerative medicine. *Stem Cell Rev Rep* 7:269–291
44. Stahl A, Connor KM, Sapienza P et al (2010) The mouse retina as an angiogenesis model. *Invest Ophthalmol Vis Sci* 51:2813–2826
45. Cai J, Kehoe O, Smith GM, Hykin P, Boulton ME (2008) The angiopoietin/tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. *Invest Ophthalmol Vis Sci* 49:2163–2171
46. Armulik A, Genove G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev Cell* 21:193–215
47. Ayalasomayajula SP, Kompella UB (2003) Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. *Eur J Pharmacol* 458:283–289
48. Sennlaub F, Valamanesh F, Vazquez-Tello A et al (2003) Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. *Circulation* 108:198–204
49. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S (2008) Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. *J Biol Chem* 283:2139–2146
50. Gomez I, Foudi N, Longrois D, Norel X (2013) The role of prostaglandin E2 in human vascular inflammation. *Prostaglandins Leukot Essent Fatty Acids* 89:55–63